20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ginkgo Bioworks Holdings (DNA) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 485 employees. Its market capitalization is roughly $755 million. In the fiscal year ended 2025-12-31, DNA reported $170M in revenue and ($313M) in net income.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Interactive charts & full statements → Open the DNA valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $112M | $170M | $227M | $251M | $478M | $314M | $77M | $54M |
| Gross Profit | $90M | $139M | $188M | $197M | $273M | $184M | $61M | $54M |
| Gross Margin % | 80.1% | 81.5% | 83.0% | 78.5% | 57.2% | 58.7% | 79.6% | 100.0% |
| Operating Income (EBIT) | ($291M) | ($315M) | ($560M) | ($864M) | ($2.2B) | ($1.8B) | ($137M) | ($72M) |
| Operating Margin % | -259.9% | -185.3% | -246.5% | -343.8% | -462.4% | -582.6% | -178.8% | -132.1% |
| Net Income | ($291M) | ($313M) | ($547M) | ($893M) | ($2.1B) | ($1.8B) | ($127M) | ($119M) |
| Net Margin % | -260.0% | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% | -220.2% |
| EBITDA | ($209M) | ($255M) | ($484M) | ($821M) | ($2.1B) | ($1.8B) | ($109M) | ($107M) |
| Earnings Per Share (EPS) | $-5.05 | $-5.64 | $-10.54 | $-18.37 | $-50.12 | $-53.81 | $-3.97 | $-4.15 |
| Shares Outstanding (M) | 62M | 55M | 52M | 49M | 42M | 34M | 32M | 29M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $20M | $19M | $33M | $39M | $50M | $48M | $44M | $89M |
| Gross Profit | $18M | $4M | $42M | $26M | $35M | $36M | $34M | $79M |
| Gross Margin % | 91.5% | 18.4% | 124.4% | 67.0% | 70.1% | 75.1% | 78.1% | 88.8% |
| Operating Income (EBIT) | ($59M) | ($71M) | ($71M) | ($90M) | ($66M) | ($89M) | ($104M) | ($55M) |
| Operating Margin % | -290.5% | -366.5% | -211.9% | -231.8% | -132.1% | -184.1% | -236.3% | -62.0% |
| Net Income | ($47M) | ($83M) | ($81M) | ($81M) | ($60M) | ($91M) | ($108M) | ($56M) |
| Net Margin % | -231.7% | -424.1% | -241.8% | -207.9% | -121.6% | -188.2% | -245.2% | -63.3% |
| EBITDA | ($44M) | ($63M) | ($35M) | ($67M) | ($46M) | ($68M) | ($143M) | ($35M) |
| Earnings Per Share (EPS) | $-0.75 | $-1.39 | $-1.46 | $-1.45 | $-1.10 | $-1.68 | $-2.07 | $-1.08 |
| Shares Outstanding (M) | 62M | 60M | 55M | 56M | 55M | 54M | 52M | 52M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($170M) | ($171M) | ($320M) | ($296M) | ($252M) | ($254M) | ($136M) | ($45M) |
| Capital Expenditures (CapEx) | $28M | $8M | $63M | $41M | $52M | $57M | $58M | $22M |
| Free Cash Flow (FCF) | ($198M) | ($179M) | ($382M) | ($336M) | ($304M) | ($310M) | ($194M) | ($67M) |
| FCF Margin % | -176.8% | -105.0% | -168.3% | -133.7% | -63.7% | -98.9% | -252.6% | -123.4% |
| Dividends Paid | — | — | — | — | $1M | $1.5B | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($44M) | ($47M) | ($48M) | ($32M) | ($40M) | ($52M) | ($42M) | ($104M) |
| Capital Expenditures (CapEx) | $3M | $2M | $15M | $8M | $0M | $8M | $14M | $15M |
| Free Cash Flow (FCF) | ($47M) | ($49M) | ($63M) | ($39M) | ($40M) | ($59M) | ($56M) | ($119M) |
| FCF Margin % | -232.6% | -249.7% | -188.7% | -101.1% | -81.2% | -122.4% | -128.1% | -133.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $990M | $1.1B | $1.4B | $1.7B | $2.5B | $2.1B | $675M | $697M |
| Cash & Cash Equivalents | $85M | $167M | $562M | $944M | $1.3B | $1.6B | $381M | $495M |
| Total Liabilities | $570M | $611M | $661M | $568M | $803M | $504M | $205M | $195M |
| Total Debt (Short + Long-Term) | $0M | $23M | $29M | $17M | $29M | $1M | $0M | $1M |
| Total Shareholders' Equity | $420M | $509M | $716M | $1.1B | $1.7B | $1.5B | $461M | $493M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DNA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms